Skip to main content

Hepatitis C Virus Infection

Infectious Diseases
53
Pipeline Programs
10
Companies
50
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
22
1
23
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
10100%
+ 83 programs with unclassified modality

Infectious Diseases is an $11.9B market dominated by HIV and hepatitis C treatments in their peak revenue phases, reflecting a mature but stable therapeutic area.

$11.9B marketMature→ Stable30 products15 companies

Key Trends

  • HIV antiretroviral dominance: Nucleoside Reverse Transcriptase Inhibitors account for 44% of spending
  • Patent cliff pressure: $2.8B in revenue from major products facing LOE between 2027–2031
  • High trial velocity: 9,337 active trials indicate sustained pipeline development despite market maturity

Career Verdict

Infectious Diseases offers stable, well-compensated roles with strong commercial demand, but limited growth upside—ideal for risk-averse professionals seeking established franchises rather than high-growth opportunities.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1BIKTARVYStable
$3.2B
Gilead Sciences·Peak10.5yr
#2EPCLUSAStable
$877M
Gilead Sciences·Peak8.2yr
#3TIVICAYDeclining
$657M
GSK·Peak4.1yr
#4TRIUMEQDeclining
$632M
GSK·Peak4.1yr
#5GENVOYAStable
$626M
Gilead Sciences·Peak6.9yr

Drug Class Breakdown

Nucleoside Reverse Transcriptase Inhibitors
$5.2B(44%)

backbone of HIV treatment, stable demand

RNA Replicase Inhibitors
$1.8B(15%)

hepatitis C treatment, mature market

Cytochrome P450 3A Inhibitors
$1.4B(12%)

boosting agents in combination regimens

P-Glycoprotein Inhibitors
$343M(3%)

niche mechanism, limited growth

Career Outlook

Stable

Infectious Diseases offers predictable career progression and above-average compensation in Commercial roles, supported by 780 current openings and sustained demand from market incumbents. However, patent cliffs affecting $2.8B in near-term revenue (2027–2031) will compress margins and slow hiring after 2028, particularly in Commercial support and field-based roles. The area is best suited for mid-career professionals seeking stability over rapid growth, with limited appeal for early-career scientists pursuing innovation-driven research.

Breaking In

Enter via Commercial or Manufacturing roles at GSK, Sanofi, or Becton Dickinson to build market expertise and commanding salaries ($160K–$237K); avoid pure R&D tracks unless you target specific mechanisms like long-acting injectables.

For Experienced Professionals

Experienced professionals should pursue Market Access, Medical Affairs, or Commercial Leadership roles where patent cliff expertise commands premium compensation; consider consulting or biotech transition if R&D innovation is your priority.

In-Demand Skills

Market access and payer strategyBrand management in generic-transition environmentsManufacturing scale-up and supply chain optimizationMedical science liaison (MSL) capabilities for physician engagementHealth economics and real-world outcomes analysis

Best For

Brand ManagerMarket Access ManagerMedical Science LiaisonSales DirectorManufacturing EngineerHealth Economics Analyst

Hiring Landscape

$160K–$275K

Infectious Diseases hiring is heavily weighted toward Commercial roles (247 positions, 32% of total), reflecting mature market dynamics focused on market access and brand management. GSK and Becton Dickinson lead hiring (214 and 188 roles), but Gilead Sciences—the market leader by revenue—shows surprisingly low hiring (25 roles), signaling efficiency-driven operations. Salary progression favors Commercial ($275K avg) over R&D ($184K avg), indicating career acceleration through sales and marketing functions.

780
Open Roles
5
Companies Hiring
4
Departments

Top Hiring Companies

GSK
214Growing
Becton Dickinson
188Growing
Sanofi
100Stable
Merck & Co.
61Stable
Verona Pharma
51Growing

By Department

Commercial(32%)
$275K
Engineering(16%)
$237K
Manufacturing(14%)
$160K
Research & Development(9%)
$184K

Strong Commercial hiring with premium salaries suggests Infectious Diseases is an excellent landing spot for brand, sales, and market access professionals, but limited R&D hiring indicates reduced innovation investment.

On Market (2)

Approved therapies currently available

Gilead Sciences
EPCLUSAApproved
velpatasvir and sofosbuvir
Gilead Sciences
Hepatitis C Virus NS5A Inhibitor [EPC]oral2016
877M Part D
Gilead Sciences
SOVALDIApproved
sofosbuvir
Gilead Sciences
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]oral2013
2M Part D

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Kite Pharma
Kite PharmaCA - El Segundo
46 programs
1
20
21
1
SofosbuvirPhase 4Small Molecule1 trial
LDV/SOFPhase 31 trial
LDV/SOFPhase 31 trial
LDV/SOFPhase 31 trial
LDV/SOFPhase 31 trial
+41 more programs
Active Trials
NCT02537379Completed552Est. Jun 2017
NCT02510300Terminated461Est. Jan 2023
NCT02292706Terminated1,609Est. Dec 2021
+43 more trials
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
34 programs
1
SOFN/A
SofosbuvirN/ASmall Molecule
SofosbuvirN/ASmall Molecule
LDV/SOFPHASE_2
LDV/SOFPHASE_2
+29 more programs
AbbVie
AbbVieNORTH CHICAGO, IL
6 programs
1
1
2
ABT-493 coformulated with ABT-530Phase 31 trial
ABT-493/ABT-530Phase 31 trial
ABT-450/r/ABT-267Phase 2/31 trial
ABT-072Phase 2
glecaprevirN/ASmall Molecule1 trial
+1 more programs
Active Trials
NCT03123965Approved For Marketing
NCT07419347Recruiting2,000Est. Jun 2026
NCT04903626Completed286Est. Sep 2024
+6 more trials
Abbott
AbbottABBOTT PARK, IL
1 program
1
ABT-072Phase 21 trial
Active Trials
NCT00872196Completed5Est. Apr 2010
MSD
MSDIreland - Ballydine
1 program
1
200 mg MK-1075Phase 1
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
200 mg MK-1075Phase 11 trial
Active Trials
NCT02461563Completed12Est. Dec 2015
Akros Pharma
Akros PharmaNJ - Princeton
1 program
1
JTK-853Phase 13 trials
Active Trials
NCT01473056Completed29Est. Sep 2011
NCT01473069Terminated41Est. Jul 2010
NCT01475981Completed70Est. Apr 2010
Chugai Pharma
Chugai PharmaJapan - Tokyo
1 program
SOFN/A
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
200 mg MK-1075PHASE_1
Bristol Myers Squibb
1 program
BMS-791325PHASE_15 trials
Active Trials
NCT02309450Withdrawn0Est. Aug 2016
NCT00947245Withdrawn0Est. Feb 2015
NCT02098616Completed25Est. Feb 2016
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbVieglecaprevir/pibrentasvir
Kite PharmaSofosbuvir
AbbVieglecaprevir/pibrentasvir
Kite PharmaSOF/VEL
Kite PharmaSOF/VEL
AbbVieglecaprevir/pibrentasvir
AbbVieglecaprevir/pibrentasvir
AbbVieglecaprevir/pibrentasvir
AbbVieglecaprevir/pibrentasvir
AbbVieglecaprevir/pibrentasvir
Kite PharmaSOF/VEL/VOX
AbbVieglecaprevir/pibrentasvir
AbbVieglecaprevir/pibrentasvir
Kite PharmaSOF/VEL
AbbVieglecaprevir/pibrentasvir

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 9,315 patients across 50 trials

NCT03781726AbbVieglecaprevir/pibrentasvir

Multi-center Study to Transplant Hepatitis-C Infected Kidneys

Start: Apr 2019Est. completion: Dec 202130 patients
Phase 4Completed
NCT02128542Kite PharmaSofosbuvir

Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis

Start: Jun 2014Est. completion: Jun 201566 patients
Phase 4Completed
NCT04903626AbbVieglecaprevir/pibrentasvir

Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

Start: Aug 2021Est. completion: Sep 2024286 patients
Phase 3Completed
NCT04211909Kite PharmaSOF/VEL

Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

Start: Jan 2020Est. completion: Nov 202087 patients
Phase 3Completed
NCT04112303Kite PharmaSOF/VEL

Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis

Start: Oct 2019Est. completion: Jun 202137 patients
Phase 3Completed
NCT03219216AbbVieglecaprevir/pibrentasvir

A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection

Start: Jun 2018Est. completion: Mar 2019100 patients
Phase 3Completed
NCT03222583AbbVieglecaprevir/pibrentasvir

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection

Start: Oct 2017Est. completion: Feb 2019546 patients
Phase 3Completed
NCT03235349AbbVieglecaprevir/pibrentasvir

Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection

Start: Sep 2017Est. completion: Feb 2019160 patients
Phase 3Completed
NCT03212521AbbVieglecaprevir/pibrentasvir

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

Start: Aug 2017Est. completion: Aug 2018230 patients
Phase 3Completed
NCT03089944AbbVieglecaprevir/pibrentasvir

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

Start: Apr 2017Est. completion: Nov 2019343 patients
Phase 3Completed
NCT03118843Kite PharmaSOF/VEL/VOX

Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Start: Apr 2017Est. completion: Mar 201831 patients
Phase 3Completed
NCT03092375AbbVieglecaprevir/pibrentasvir

Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects

Start: Apr 2017Est. completion: Feb 2020177 patients
Phase 3Completed
NCT03069365AbbVieglecaprevir/pibrentasvir

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment

Start: Mar 2017Est. completion: Jun 2018101 patients
Phase 3Completed
NCT03074331Kite PharmaSOF/VEL

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

Start: Mar 2017Est. completion: Feb 2018130 patients
Phase 3Completed
NCT02966795AbbVieglecaprevir/pibrentasvir

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection

Start: Jan 2017Est. completion: Aug 201884 patients
Phase 3Completed
NCT02996682Kite PharmaSOF/VEL

Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis

Start: Dec 2016Est. completion: May 2018102 patients
Phase 3Completed
NCT02939989AbbVieglecaprevir/pibrentasvir

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

Start: Nov 2016Est. completion: Jul 202133 patients
Phase 3Completed
NCT02822794Kite PharmaSOF/VEL

Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen

Start: Jul 2016Est. completion: Aug 2017117 patients
Phase 3Completed
NCT02634008AbbVieglecaprevir/pibrentasvir

Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P

Start: Jun 2016Est. completion: Apr 202183 patients
Phase 3Completed
NCT02738138AbbVieABT-493 coformulated with ABT-530

A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)

Start: May 2016Est. completion: Jun 2017153 patients
Phase 3Completed
NCT02692703AbbVieglecaprevir/pibrentasvir

A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)

Start: Apr 2016Est. completion: Jun 2017100 patients
Phase 3Completed
NCT02671500Kite PharmaSOF/VEL

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV

Start: Apr 2016Est. completion: Mar 2018375 patients
Phase 3Completed
NCT02738333Kite PharmaLDV/SOF

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection

Start: Apr 2016Est. completion: May 2017239 patients
Phase 3Completed
NCT02722837Kite PharmaSOF/VEL

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection

Start: Apr 2016Est. completion: Sep 2017119 patients
Phase 3Completed
NCT02639338Kite PharmaSOF/VEL/VOX

Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis

Start: Dec 2015Est. completion: Jan 2017220 patients
Phase 3Completed
NCT02639247Kite PharmaSOF/VEL/VOX

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor

Start: Dec 2015Est. completion: Jan 2017333 patients
Phase 3Completed
NCT02613871Kite PharmaLDV/SOF

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection

Start: Dec 2015Est. completion: Nov 2018111 patients
Phase 3Completed
NCT02642432AbbVieABT-493/ABT-530

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis

Start: Dec 2015Est. completion: Feb 2017146 patients
Phase 3Completed
NCT02600351Kite PharmaLDV/SOF

Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies

Start: Nov 2015Est. completion: May 201787 patients
Phase 3Terminated
NCT02487030Kite PharmaLDV/SOF

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection

Start: Sep 2015Est. completion: Feb 2017255 patients
Phase 3Completed
NCT02480712Kite PharmaSOF/VEL

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

Start: Jul 2015Est. completion: Jun 2016107 patients
Phase 3Completed
NCT02472886Kite PharmaLDV/SOF

Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection

Start: Jun 2015Est. completion: Jun 2016153 patients
Phase 3Completed
NCT02346721Kite PharmaSOF/VEL

Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection

Start: Feb 2015Est. completion: Jun 2016111 patients
Phase 3Completed
NCT02220998Kite PharmaSOF/VEL

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection

Start: Sep 2014Est. completion: Sep 2015269 patients
Phase 3Completed
NCT02201940Kite PharmaSOF/VEL

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection

Start: Jul 2014Est. completion: Sep 2015741 patients
Phase 3Completed
NCT02201953Kite PharmaSOF/VEL

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection

Start: Jul 2014Est. completion: Dec 2015558 patients
Phase 3Completed
NCT02201901Kite PharmaSOF/VEL

Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis

Start: Jul 2014Est. completion: Nov 2015268 patients
Phase 3Completed
NCT02170727Bristol Myers SquibbBMS-791325

A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1

Start: Jun 2014Est. completion: Sep 2015199 patients
Phase 3Completed
NCT02123654Bristol Myers SquibbBMS-791325

UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C

Start: Apr 2014Est. completion: Aug 2015297 patients
Phase 3Completed
NCT01979939Bristol Myers SquibbBMS-791325

UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects

Start: Dec 2013Est. completion: Nov 2014416 patients
Phase 3Completed
NCT01973049Bristol Myers SquibbBMS-791325

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

Start: Dec 2013Est. completion: Nov 2014202 patients
Phase 3Completed
NCT03067129AbbVieglecaprevir/pibrentasvir

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

Start: Mar 2017Est. completion: Sep 2022129 patients
Phase 2/3Completed
NCT01939197AbbVieABT-450/r/ABT-267

A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection

Start: Aug 2013Est. completion: Oct 2016318 patients
Phase 2/3Completed
NCT03820258Kite PharmaSOF/VEL/VOX

Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection

Start: Jan 2019Est. completion: Feb 202021 patients
Phase 2Terminated
NCT03036839Kite PharmaLDV/SOF

Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease

Start: Jun 2017Est. completion: Feb 201995 patients
Phase 2Completed
NCT03022981Kite PharmaSOF/VEL

Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection

Start: Jan 2017Est. completion: Feb 2020216 patients
Phase 2Completed
NCT02994056Kite PharmaSOF/VEL

Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis

Start: Jan 2017Est. completion: Dec 201832 patients
Phase 2Completed
NCT02868242Kite PharmaLDV/SOF

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy

Start: Aug 2016Est. completion: Feb 201919 patients
Phase 2Completed
NCT02781558Kite PharmaSOF/VEL

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis

Start: Jul 2016Est. completion: Oct 2017204 patients
Phase 2Completed
NCT02781571Kite PharmaSOF/VEL

Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant

Start: Jul 2016Est. completion: Jul 201779 patients
Phase 2Completed

Related Jobs in Infectious Diseases

Quality Oversight and Compliance Director

PfizerPfizer
United Kingdom - Walton Oaks; Europe - Any Pfizer Site; United Kingdom - Sandwich
Yesterday

Marketing & Event Coordinator (สัญญาจ้าง 1 ปี)

PfizerPfizer
Thailand - Bangkok
Yesterday

Associate Scientist - Viral Vaccines

PfizerPfizer
United States - New York - Pearl River
Yesterday
$60K - $100K/yr

Associate Scientist

PfizerPfizer
United States - New York - Pearl River
Yesterday
$60K - $100K/yr

Medical Scientific Liaison – Molecular (Pacific Northwest, U.S.)

RocheRoche
Indianapolis; Salt Lake City; Portland; Oregon; Seattle
Yesterday
$133K - $247K/yr

Key Account Manager, Vaccines

Merck & Co.Merck & Co.
FIN - Uusimaa - Espoo (Keilaniementie) (Hybrid)
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

23 late-stage (Phase 3) programs, potential near-term approvals
10 companies competing in this space

Related Indications

HIV Infections(1639)Influenza(759)COVID-19(690)HIV(630)Hepatitis C(460)HIV-1-infection(419)Hepatitis C, Chronic(322)Hepatitis B(320)HIV Infection(293)Malaria(289)

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.